Uncategorized

Sermorelin stimulates growth hormone release, but no FDA-approved product is marketed today. Geref history, evidence, side effects, dosing and WADA status.

Zenagamtide, formerly known as Amycretin, is one of Novo Nordisk’s most advanced next-generation obesity drugs. Unlike semaglutide, which activates the GLP-1 receptor, zenagamtide is a single peptide designed to activate both GLP-1 and amylin receptors. The drug is also unusual because Novo Nordisk is developing it in two forms: a once-daily oral formulation and a … Read more

Petrelintide is an investigational once-weekly amylin analog now in Phase 3. See ZUPREME-1 results (up to 10.7% weight loss), side effects and trial design.

Enicepatide (CT-388) produced 22.5% placebo-adjusted weight loss in Phase 2. Compare its results, side effects and status with tirzepatide.